TXG vs. OLK, CTKB, BIO.B, BIO, IDYA, AMED, SHC, IRTC, SWTX, and XENE
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Olink Holding AB (publ) (OLK), Cytek Biosciences (CTKB), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), IDEAYA Biosciences (IDYA), Amedisys (AMED), Sotera Health (SHC), iRhythm Technologies (IRTC), SpringWorks Therapeutics (SWTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "medical" sector.
Olink Holding AB (publ) (NASDAQ:OLK) and 10x Genomics (NASDAQ:TXG) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
30.2% of Olink Holding AB (publ) shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 5.2% of Olink Holding AB (publ) shares are held by company insiders. Comparatively, 10.7% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Olink Holding AB (publ) has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.
Olink Holding AB (publ) has a net margin of -19.72% compared to Olink Holding AB (publ)'s net margin of -42.20%. 10x Genomics' return on equity of -7.07% beat Olink Holding AB (publ)'s return on equity.
10x Genomics received 29 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.
Olink Holding AB (publ) has higher earnings, but lower revenue than 10x Genomics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
Olink Holding AB (publ) currently has a consensus price target of $26.00, suggesting a potential upside of 8.56%. 10x Genomics has a consensus price target of $48.50, suggesting a potential upside of 89.53%. Given Olink Holding AB (publ)'s stronger consensus rating and higher probable upside, analysts clearly believe 10x Genomics is more favorable than Olink Holding AB (publ).
In the previous week, Olink Holding AB (publ) had 11 more articles in the media than 10x Genomics. MarketBeat recorded 15 mentions for Olink Holding AB (publ) and 4 mentions for 10x Genomics. Olink Holding AB (publ)'s average media sentiment score of 0.90 beat 10x Genomics' score of -0.09 indicating that 10x Genomics is being referred to more favorably in the news media.
Summary
10x Genomics beats Olink Holding AB (publ) on 11 of the 18 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10x Genomics Competitors List
Related Companies and Tools
